TAG:
Histology
Histology
Histology is a branch of anatomy that deals with the study structure of animal and plant tissues that is only discernible with a microscope. It is also called microscopic anatomy, as opposed to gross anatomy, which involves structures that can be observed with the naked eye. The word “histology” is derived from two Greek words: histo, which means “tissue,” and logos, which means “study.”
Histopathology, the microscopic study of diseased tissue, is an important tool used in anatomical pathology, as accurate diagnosis of cancer and other diseases usually requires histopathological examination of samples.
Histological studies are often carried out by examining a thin slice (called a “section”) of tissue under a light microscope or an electron microscope on a prepared slide.
In order to distinguish different biological structures more easily and accurately, histological stains are often used to add colors to, or enhance the colors of, certain types of biological structures to allow them to be more easily differentiated from other types of structures. Staining is employed because biological tissue has little inherent contrast when observed using either light or electron microscopes.
Trained physicians, frequently licensed clinical pathologists, are the personnel who actually perform histopathological examinations and provide diagnostic information based on their observations of the tissues being tested.
The trained personnel who prepare histological specimens for examination may go by a number of titles, including:
- Histotechnician
- Histology technician (HT)
- Histology technologists (HTL)
- Medical scientists
- Medical laboratory technician
- Biomedical scientist
Their field of study is called histotechnology.
Histology has seen recent changes as technological advances in automation have influenced the field. Automation allows for the reduction of the workload of manual task needed to prepare and track histology specimens. Artificial intelligence also is playing a growing role in supporting the analysis of sections, supporting anatomic pathologists during their examinations of samples.
TOP 10 LAB STORIES OF 2017
By Robert Michel | From the Volume XXIV No. 17 – December 11, 2017 Issue
1. CMS Sticks by Decision to Deeply Cut Medicare Part B Lab Test Fees SHORT OF A MIRACLE, the clinical laboratory industry is less than three weeks from the single most financially-disruptive event of the past 30 years. On Jan. 1, the federal Centers for Medicare and Medicaid Service…
USC’s Clive Taylor, MD, Talks Digital Path, WSI
By Joseph Burns | From the Volume XXIV No. 10 – July 17, 2017 Issue
CEO SUMMARY: The FDA’s clearance of the first digital pathology system for use in primary diagnosis will be a disruptive force for pathologists in the coming years. At the University of Southern California Keck School of Medicine, pathologist Clive Taylor, MD, predicts that the benefits of …
Digital Pathology Systems Will Create Opportunities
By R. Lewis Dark | From the Volume XXIV No. 7 – May 15, 2017 Issue
CEO SUMMARY: Advanced Pathology Associates, a 15-member private pathology group practice, had the distinction of generating data for the clinical study that Philips submitted to the Food and Drug Administration for review of its whole slide imaging system. Following the FDA’s decision t…
FDA Clears Digital Path for Primary Diagnosis
By Joseph Burns | From the Volume XXIV No. 6 – April 24, 2017 Issue
CEO SUMMARY: Proponents of digital pathology systems and whole slide imaging achieved a milestone on April 12 when the FDA cleared the Philips digital pathology system for sale in the United States. Now pathologists can use the system to perform primary diagnoses and get paid for those pr…
Philips digital pathology system scores huge success as FDA clears digital path for primary diagnosis
By Mary Van Doren | From the Volume XXIV No. 6 – April 24, 2017 Issue
This is an excerpt from a 1,400-word article in the April 24, 2017, issue of THE DARK REPORT. The complete article is available for a limited time to all readers, and available at all times to paid members of the Dark Intelligence Group. …
PAMA Economics Drives Merger Of Two Seattle-Area Pathology Groups
By Joseph Burns | From the Volume XXIV No. 1 – January 9, 2017 Issue
CEO SUMMARY: Among the three chief reasons for the merger of CellNetix and Puget Sound Institute of Pathology, the most compelling was the need to address the challenges in the current reimbursement environment and to prepare for reductions in payment to pathologists expected in the comin…
Ohio State University Medical Center Inks Pact To Adopt Digital Pathology
By Joseph Burns | From the Volume XXIII No. 11 – August 15, 2016 Issue
CEO SUMMARY: For years, the adoption of digital pathology has lagged behind the predictions of its advocates. That has encouraged one digital pathology company—Inspirata, Inc., of Tampa—to come up with a different business strategy designed to help anatomic pathology labs address the …
UnitedHealthcare Warns Labs Not to Waive Patient Fees
By Joseph Burns | From the Volume XXIII No. 4 – March 21, 2016 Issue
CEO SUMMARY: UnitedHealthcare directly tackled the issue of out-of-network labs waiving or capping copayments, coinsurance and deductibles that are to be paid by patients. In a network bulletin this month, UHC said that such arrangements may violate federal law and could lead to state ins…
Does Private Practice Pathology Have a Future?
By R. Lewis Dark | From the Volume XXIII No. 3 – February 29, 2016 Issue
IN RECENT DECADES, A PROPORTION OF PATHOLOGISTS has been proud of the fact that the pathology profession—to a large extent—had managed to protect the vast majority of private pathology group practices from any number of powerful trends and market forces. In the 1990s, HMO contracting practices t…
January 19, 2016 Intelligence: Late Breaking Lab News
By Robert Michel | From the Volume XXIII, No. 1 – January 19, 2016 Issue
Sakura Finetek USA, Inc., announced on January 5 that it had acquired 100% of the stock of GeneMed Biotechnologies Inc., of South San Francisco, California, along with its “tissue-based advanced staining business for cancer detection, diagnosis, and monitoring.”…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized